Research Library › Neuropeptides
Melanotan I is the former name of afamelanotide, a synthetic 13-amino-acid linear analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also known as [Nle4, D-Phe7]-alpha-MSH. It was first described in 1980 by Victor Hruby, Mac Hadley and colleagues at the University of Arizona. As of October 2026 afamelanotide is approved only as Clinuvel’s Scenesse implant (EU 2014, US 2019) for a rare genetic photosensitivity disorder; products sold as “Melanotan I” are not approved drugs.
Key facts
| Type | Synthetic linear 13-amino-acid peptide; analog of alpha-MSH |
|---|---|
| Other names | Afamelanotide (INN), [Nle4, D-Phe7]-alpha-MSH, NDP-MSH, MT-I; brand Scenesse |
| Developed by | Victor Hruby, Mac Hadley, Robert Dorr and colleagues, University of Arizona; later Clinuvel Pharmaceuticals |
| First described | 1980, Proceedings of the National Academy of Sciences |
| Designed target | Melanocortin receptors, binding predominantly to the melanocortin 1 receptor (MC1R) |
| Regulatory status (Oct 2026) | Approved only as Scenesse (afamelanotide implant): EU 2014, FDA 2019, for erythropoietic protoporphyria; other "Melanotan I" products unapproved |
Who developed it
Melanotan I came out of the University of Arizona in Tucson. A 1980 paper by T. K. Sawyer, Victor Hruby, Mac Hadley and co-workers described the molecule now called afamelanotide [1]. The university credits Hruby, a chemist, Hadley, a cell biologist, and Robert Dorr, a pharmacologist at the UA Cancer Center, with developing, patenting and first testing it [2].
The university licensed the molecule in 1995 to Melanotan Inc., which it describes as a predecessor company to Clinuvel Pharmaceuticals of Melbourne, Australia. Clinuvel took afamelanotide through regulatory approval [2, 6]. In their 2006 history of melanocortin drugs, Hadley and Dorr noted that Melanotan I had been patented and tested in clinical studies, and disclosed that they received royalties from its commercialization [3].
Structure and design
Afamelanotide is a modified version of alpha-MSH, a natural 13-amino-acid hormone. Two substitutions define it: norleucine replaces methionine at position 4, and the mirror-image amino acid D-phenylalanine replaces L-phenylalanine at position 7 [1]. The 1980 paper reported that these changes made the peptide resistant to breakdown by serum enzymes in laboratory assays [1].
The FDA label gives its sequence as Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, a linear peptide with a molecular weight of about 1,647 daltons. The label describes it as a melanocortin receptor agonist that binds predominantly to MC1R [5]. Its linear form distinguishes it from the shorter, cyclic Melanotan II [3].
Research history
The Arizona group originally designed long-acting alpha-MSH analogs to probe how melanocortin receptors work [1, 3]. Early human studies ran at the UA Cancer Center under a skin-cancer chemoprevention grant, with first results published in 1991 [2].
- 1980: [Nle4, D-Phe7]-alpha-MSH first described [1]
- 1991: First human study results published [2]
- 1995: University of Arizona licenses the molecule to Melanotan Inc. [2]
- 2008: EU orphan designation for erythropoietic protoporphyria [4]
- 2014: European Commission authorizes Scenesse [4]
- 2019: FDA approves Scenesse [5, 6]
Regulatory status as of October 2026
The European Commission authorized Scenesse (afamelanotide implant) on 22 December 2014 for adults with erythropoietic protoporphyria (EPP), a rare inherited condition causing phototoxic reactions to light. It was granted under “exceptional circumstances” because the disease is rare [4]. The FDA approved Scenesse in October 2019 for adults with EPP and a history of phototoxic reactions [5, 6].
These approvals cover only Clinuvel’s implant. Products marketed online as “Melanotan I” are not approved by the FDA or any other regulator and are not equivalent to the approved medicine.
Scenesse held EU orphan designation from 2008. The designation was withdrawn from the EU orphan register in December 2024, at the end of the product’s ten-year market exclusivity period; the marketing authorization itself remains in place [4].
About this reference page
Kalibra Labs does not currently supply Melanotan I (afamelanotide). This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Is Melanotan I the same as afamelanotide?
Yes. Afamelanotide is the international nonproprietary name for the peptide originally called Melanotan I, also written [Nle4, D-Phe7]-alpha-MSH [2, 5].
Who invented Melanotan I?
It was created at the University of Arizona; the first paper, in 1980, came from Sawyer, Hruby, Hadley and colleagues, and Robert Dorr later led early clinical work [1, 2].
Is afamelanotide FDA approved?
Yes, but only as Scenesse, an implant approved in 2019 for adults with erythropoietic protoporphyria. Other products sold as Melanotan I are not FDA-approved [5, 6].
How is Melanotan I different from Melanotan II?
Melanotan I is a linear 13-amino-acid peptide, while Melanotan II is a shorter, cyclic peptide developed later by the same Arizona group [3].
Sources
- Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754. Link
- University of Arizona Cancer Center. UA-discovered drug for skin disease approved for patients in Europe. News release, Oct 2014. Link
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029. Link
- European Medicines Agency. Scenesse (afamelanotide): EPAR, product information and authorisation details. Link
- U.S. FDA. SCENESSE (afamelanotide) implant, prescribing information, NDA 210797; initial U.S. approval 2019. Link
- Clinuvel Pharmaceuticals. FDA approves SCENESSE for genetic disorder. Press release, 8 Oct 2019. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
